{"success":true,"data":{"pressRelease":{"id":"133591","rtpr_id":"nBw4LwFLca","ticker":"BLCO","exchange":"TSX","all_tickers":["BLCO"],"title":"Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience","author":"Business Wire","published_at":"2026-09-02T11:00:00.182Z","article_body":"Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World\nExperience\n\n\n * Multicenter retrospective case series published in Ophthalmology and Therapy\n\n * Results demonstrate enVista Aspire and enVista Aspire toric deliver good\ndistance and functional intermediate vision in a majority of patients\n\n * Study shows these enhanced monofocal lenses can meet digital demands modern\ncataract patients face\n\n * This \npaper\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fecp.bausch.com%2Fpublications%2Flibrary%2Freal-world-experience-enhanced-monofocal-intraocular-lenses-cataract-surgery%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=paper&index=1&md5=61063e608f9c049e1504f89d60ed4b80)\n\nand other data on enVista Aspire can be found on Bausch + Lomb’s new \nEye Care Professional Hub\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fecp.bausch.com%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Eye+Care+Professional+Hub&index=2&md5=99362e9110de18f88a2ff570c92d1093)\n\nBausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health\ncompany dedicated to helping people see better to live better, today announced\nthe publication\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40123-026-01473-3&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=publication&index=3&md5=aea25643f2e230807878552f048d07b0)\nof new research on real world experience with enVista Aspire and enVista\nAspire toric intraocular lenses (IOLs). The study, published in the journal\nOphthalmology and Therapy, found that these enhanced monofocal lenses\ndelivered both good distance and functional intermediate vision, thus meeting\nthe needs of many cataract patients.\n\n“Traditional monofocal lenses offer good distance vision, but we know that\ncataract patients have an increased need and desire for good intermediate\nvision, particularly given the digital demands of our modern world,” said\nLuc Bonnefoy, president, Surgical, Bausch + Lomb. “The results of this study\nreinforce clinical data showing that the intermediate optimized optics of the\nenVista(®) Aspire platform, which are designed for a broader depth of focus,\ncan deliver both.”\n\nIn this multicenter, real-world study, six U.S.-based cataract surgeons\nprovided a sample of cataract surgery cases and completed a retrospective\nexperience survey, which captured outcomes including corrected and uncorrected\ndistance visual acuity (CDVA and UDVA), uncorrected intermediate visual acuity\n(UIVA), refractive outcomes and safety. The sample included a total of 84\npatients and 141 eyes (88 for enVista Aspire and 53 for enVista Aspire toric).\n\nKey points from the trial:(1)\n\n\n * In the enVista Aspire patient group, 97.2% attained a monocular CDVA of 20/25\nor better, 71.3% attained a monocular UDVA of 20/25 or better and 76.6%\nattained a monocular UIVA of 20/32 or better at the last reported follow up\nappointment.\n\n * In the enVista Aspire toric group, 94.9% reached a monocular CDVA of 20/25 or\nbetter, 84.9% reached a monocular UDVA of 20/25 or better and 93% reached a\nmonocular UIVA of 20/32 or better at the last reported follow up appointment.\n\n * 100% of subjects in both groups realized a binocular UIVA of 20/32 or better.\n\n * No serious adverse events were recorded.\n\n“The results of clinical studies involving enVista Aspire lenses have been\nclear, but real-world data has thus far been limited,” said Eric Donnenfeld,\nMD, lead author of the study and ophthalmologist with Ophthalmic Consultants\nof Connecticut. “The outcomes reported in this study not only mirror what\nI’ve seen in my practice, they also provide evidence that the intermediate\noptimized optic is indeed having the intended affect in clinical practice.”\n\nUnlike standard monofocal IOLs, the enVista Aspire monofocal optic broadens\nvision beyond distance alone, into the intermediate range. Like the\nenVista(®) monofocal IOL, enVista Aspire offers a glistening-free optic\nmaterial and controlled, efficient unfolding through Bausch + Lomb’s\nproprietary StableFlex™ Technology, which aids optic recovery.\n\nFor patients with astigmatism, enVista Aspire Toric IOLs provide a proven\noption for treatment of their astigmatism during cataract surgery. From a low\ncylinder design, +1.25D in the US and +0.90D (IOL plane) in markets outside of\nthe US, enVista toric platform covers a wide range of treatment for patients\nwith corneal astigmatism. The unique AccuSet haptic design enables exceptional\nrotational stability, an important attribute for toric lenses.\n\nFor more information about enVista Aspire, visit\nhttps://www.bauschsurgical.com/cataract/enVista-Aspire/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bauschsurgical.com%2Fcataract%2FenVista-Aspire%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=https%3A%2F%2Fwww.bauschsurgical.com%2Fcataract%2FenVista-Aspire%2F&index=4&md5=0ac860bedb08bb1528acf7b95f7593b9)\n.\n\nIndications and Important Safety Information for enVista Aspire & enVista\nAspire toric hydrophobic acrylic IOLs\n\nINDICATIONS:\n\nThe enVista Aspire™ hydrophobic acrylic IOL (non-preloaded model: EA /\npreloaded into shuttle models: EPA, EC20A, EC24A) is indicated for primary\nimplantation in the capsular bag of the eye in adult patients for the visual\ncorrection of aphakia following removal of a cataractous lens.\n\nThe enVista Aspire™ toric hydrophobic acrylic IOL (non-preloaded model: ETA\n/ preloaded into shuttle models: ETPA, ETC20A, ETC24A) is indicated for\nprimary implantation in the capsular bag of the eye in adult patients for the\nvisual correction of aphakia and corneal astigmatism following the removal of\na cataractous lens for improved uncorrected distance vision.\n\nDEVICE DESCRIPTIONS:\n\nThe enVista Aspire and enVista Aspire toric IOLs use an optical modification\nof the posterior aspheric surface to create a small continuous increase in IOL\npower within the central 1.5 mm diameter to slightly broaden the depth of\nfocus.\n\nWARNINGS:\n\nenVista Aspire and enVista Aspire toric IOLs: Physicians considering IOL\nimplantation under any of the following circumstances should weigh the\npotential risk/benefit ratio: (1) Recurrent severe anterior or posterior\nsegment inflammation or uveitis; (2) Patients in whom the IOL may affect the\nability to observe, diagnose, or treat posterior segment diseases; (3)\nSurgical difficulties at the time of cataract extraction, which might increase\nthe potential for complications (e.g., persistent bleeding, significant iris\ndamage, uncontrolled positive pressure, or significant vitreous prolapse or\nloss); (4) A distorted eye due to previous trauma or developmental defect in\nwhich appropriate support of the IOL is not possible; (5) Circumstances that\nwould result in damage to the endothelium during implantation; (6) Suspected\nmicrobial infection; (7) Patients in whom neither the posterior capsule nor\nzonules are intact enough to provide support.\n\nenVista Aspire toric IOL only: Rotation of the IOL away from the intended axis\ncan reduce its astigmatic correction. Misalignment greater than 30° may\nincrease postoperative refractive cylinder. If necessary, IOL positioning\nshould occur prior to capsule fibrosis and IOL encapsulation.\n\nPRECAUTIONS:\n\n\n 1. Neither the safety and effectiveness, nor the effects of the Aspire IOL\noptical design on depth of focus, contrast sensitivity, and subjective visual\ndisturbances (glare, halo, etc.) have been evaluated clinically. MTF testing\nof the Aspire IOL optical design (used in model ETA) may aid the surgeon in\nunderstanding the theoretical image quality expected with the Aspire IOL\ncompared to the enVista monofocal IOL MX60E. However, these do not fully\nassess all aspects of clinical difficulties under all conditions. Surgeons\nmust weigh the potential benefits of the modified optical design of the Aspire\nIOL (model ETA) against the potential for risks associated with a degradation\nin vision quality and the lack of clinical data to characterize the impact of\nthe Aspire IOL optical design on contrast sensitivity and subjective visual\ndisturbance. These considerations may be especially relevant to patients with\ncertain pre-existing ocular conditions (prior corneal refractive surgery,\nirregular corneal astigmatism, severe corneal dystrophy, macular disease,\noptic nerve atrophy, etc.) or intraoperative conditions (posterior capsular\nrupture, complications in which the IOL stability could be compromised,\ninability to place IOL in capsular bag, etc).\n\n 2. The safety and effectiveness of the IOL have not been substantiated in\npatients with pre-existing ocular conditions and intraoperative complications.\nCareful preoperative evaluation and sound clinical judgment should be used by\nthe surgeon to decide the benefit/risk ratio before implanting an IOL in a\npatient with one or more of these conditions. Physicians considering IOL\nimplantation in such patients should explore the use of alternative methods of\naphakic correction and consider IOL implantation only if alternatives are\ndeemed unsatisfactory in meeting the needs of the patient.\n\n 3. Patients with preoperative problems, such as corneal endothelial disease,\nabnormal cornea, macular degeneration, retinal degeneration, glaucoma, and\nchronic drug miosis may not achieve the visual acuity of patients without such\nproblems. The physician must determine the benefits to be derived from IOL\nimplantation when such conditions exist.\n\nAdverse Events: As with any surgical procedure, there is risk involved.\nPotential complications accompanying cataract or implant surgery may include,\nbut are not limited to the following: corneal endothelial damage, infection\n(endophthalmitis), retinal detachment, vitritis, cystoid macular edema,\ncorneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon\ntransient or persistent glaucoma, and secondary surgical intervention.\nSecondary surgical interventions include but are not limited to: lens\nrepositioning, lens replacement, vitreous aspiration or iridectomy for\npupillary block, wound leak repair, and retinal detachment repair.\n\nCAUTION: Federal law restricts these devices to sale by or on the order of a\nphysician.\n\nATTENTION: This is not all you need to know. Please refer to the enVista\nAspire and enVista Aspire toric IOL Directions For Use labeling for a complete\nlisting of indications, full risk and safety information, clinical study\ninformation, etc.\n\nAbout Bausch + Lomb\n\nOur mission is simple – we help people see better to live better, all over\nthe world. For nearly two centuries we’ve evolved with the changing needs of\npatients and customers, and our commitment to innovation and improving the\nstandard of care in eye health has never been stronger. From contact lenses to\nprescription products, over-the-counter options, surgical devices and more,\nwe’re turning bold ideas into better outcomes through passion, perseverance\nand purpose. Learn more at www.bausch.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bausch.com%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=www.bausch.com&index=5&md5=5b488686f2577ef8764769bb61946177)\nand connect with us on Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FBauschandLomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Facebook&index=6&md5=a3c04fe5a494bce2c7a060e823867367)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fbauschlomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Instagram&index=7&md5=1ab727e903c855d14f97c5a05d13a28e)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbausch-%26-lomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=LinkedIn&index=8&md5=c55c05bce7d8833752301c7618a9a9d6)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FBauschLomb&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=X&index=9&md5=5fdaf45c47d9a0d82294b6a6a10730b7)\nand YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fbauschlomb1&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=YouTube&index=10&md5=5c3612cbd8ea0e69b1d4c5d2616f98ea)\n.\n\nReferences\n\n\n 1. Donnenfeld, E., Patel, R., Patterson, M., et al. Real-World Experience with\nEnhanced Monofocal Intraocular Lenses Following Cataract Surgery: A\nMulticenter Retrospective Case Series. Ophthalmol Ther (2026). \nhttps://doi.org/10.1007/s40123-026-01473-3\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40123-026-01473-3&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40123-026-01473-3&index=11&md5=b21da6d0aaf6217ffdb17c4e89142b58)\n\n© 2026 Bausch + Lomb.\n\nEASP.0025.USA.26\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260902448386/en/\n(https://www.businesswire.com/news/home/20260902448386/en/)\n\nMedia Contact: \n\nCaryn Marshall\n\ncaryn.marshall@bausch.com \n(mailto:caryn.marshall@bausch.com) \n(908) 493-1381\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw4LwFLca","title":"Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience","author":"Business Wire","ticker":"BLCO","created":"2026-09-02T11:00:00.182Z","tickers":["BLCO"],"exchange":"TSX","article_body":"Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World\nExperience\n\n\n * Multicenter retrospective case series published in Ophthalmology and Therapy\n\n * Results demonstrate enVista Aspire and enVista Aspire toric deliver good\ndistance and functional intermediate vision in a majority of patients\n\n * Study shows these enhanced monofocal lenses can meet digital demands modern\ncataract patients face\n\n * This \npaper\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fecp.bausch.com%2Fpublications%2Flibrary%2Freal-world-experience-enhanced-monofocal-intraocular-lenses-cataract-surgery%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=paper&index=1&md5=61063e608f9c049e1504f89d60ed4b80)\n\nand other data on enVista Aspire can be found on Bausch + Lomb’s new \nEye Care Professional Hub\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fecp.bausch.com%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Eye+Care+Professional+Hub&index=2&md5=99362e9110de18f88a2ff570c92d1093)\n\nBausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health\ncompany dedicated to helping people see better to live better, today announced\nthe publication\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs40123-026-01473-3&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=publication&index=3&md5=aea25643f2e230807878552f048d07b0)\nof new research on real world experience with enVista Aspire and enVista\nAspire toric intraocular lenses (IOLs). The study, published in the journal\nOphthalmology and Therapy, found that these enhanced monofocal lenses\ndelivered both good distance and functional intermediate vision, thus meeting\nthe needs of many cataract patients.\n\n“Traditional monofocal lenses offer good distance vision, but we know that\ncataract patients have an increased need and desire for good intermediate\nvision, particularly given the digital demands of our modern world,” said\nLuc Bonnefoy, president, Surgical, Bausch + Lomb. “The results of this study\nreinforce clinical data showing that the intermediate optimized optics of the\nenVista(®) Aspire platform, which are designed for a broader depth of focus,\ncan deliver both.”\n\nIn this multicenter, real-world study, six U.S.-based cataract surgeons\nprovided a sample of cataract surgery cases and completed a retrospective\nexperience survey, which captured outcomes including corrected and uncorrected\ndistance visual acuity (CDVA and UDVA), uncorrected intermediate visual acuity\n(UIVA), refractive outcomes and safety. The sample included a total of 84\npatients and 141 eyes (88 for enVista Aspire and 53 for enVista Aspire toric).\n\nKey points from the trial:(1)\n\n\n * In the enVista Aspire patient group, 97.2% attained a monocular CDVA of 20/25\nor better, 71.3% attained a monocular UDVA of 20/25 or better and 76.6%\nattained a monocular UIVA of 20/32 or better at the last reported follow up\nappointment.\n\n * In the enVista Aspire toric group, 94.9% reached a monocular CDVA of 20/25 or\nbetter, 84.9% reached a monocular UDVA of 20/25 or better and 93% reached a\nmonocular UIVA of 20/32 or better at the last reported follow up appointment.\n\n * 100% of subjects in both groups realized a binocular UIVA of 20/32 or better.\n\n * No serious adverse events were recorded.\n\n“The results of clinical studies involving enVista Aspire lenses have been\nclear, but real-world data has thus far been limited,” said Eric Donnenfeld,\nMD, lead author of the study and ophthalmologist with Ophthalmic Consultants\nof Connecticut. “The outcomes reported in this study not only mirror what\nI’ve seen in my practice, they also provide evidence that the intermediate\noptimized optic is indeed having the intended affect in clinical practice.”\n\nUnlike standard monofocal IOLs, the enVista Aspire monofocal optic broadens\nvision beyond distance alone, into the intermediate range. Like the\nenVista(®) monofocal IOL, enVista Aspire offers a glistening-free optic\nmaterial and controlled, efficient unfolding through Bausch + Lomb’s\nproprietary StableFlex™ Technology, which aids optic recovery.\n\nFor patients with astigmatism, enVista Aspire Toric IOLs provide a proven\noption for treatment of their astigmatism during cataract surgery. From a low\ncylinder design, +1.25D in the US and +0.90D (IOL plane) in markets outside of\nthe US, enVista toric platform covers a wide range of treatment for patients\nwith corneal astigmatism. The unique AccuSet haptic design enables exceptional\nrotational stability, an important attribute for toric lenses.\n\nFor more information about enVista Aspire, visit\nhttps://www.bauschsurgical.com/cataract/enVista-Aspire/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bauschsurgical.com%2Fcataract%2FenVista-Aspire%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=https%3A%2F%2Fwww.bauschsurgical.com%2Fcataract%2FenVista-Aspire%2F&index=4&md5=0ac860bedb08bb1528acf7b95f7593b9)\n.\n\nIndications and Important Safety Information for enVista Aspire & enVista\nAspire toric hydrophobic acrylic IOLs\n\nINDICATIONS:\n\nThe enVista Aspire™ hydrophobic acrylic IOL (non-preloaded model: EA /\npreloaded into shuttle models: EPA, EC20A, EC24A) is indicated for primary\nimplantation in the capsular bag of the eye in adult patients for the visual\ncorrection of aphakia following removal of a cataractous lens.\n\nThe enVista Aspire™ toric hydrophobic acrylic IOL (non-preloaded model: ETA\n/ preloaded into shuttle models: ETPA, ETC20A, ETC24A) is indicated for\nprimary implantation in the capsular bag of the eye in adult patients for the\nvisual correction of aphakia and corneal astigmatism following the removal of\na cataractous lens for improved uncorrected distance vision.\n\nDEVICE DESCRIPTIONS:\n\nThe enVista Aspire and enVista Aspire toric IOLs use an optical modification\nof the posterior aspheric surface to create a small continuous increase in IOL\npower within the central 1.5 mm diameter to slightly broaden the depth of\nfocus.\n\nWARNINGS:\n\nenVista Aspire and enVista Aspire toric IOLs: Physicians considering IOL\nimplantation under any of the following circumstances should weigh the\npotential risk/benefit ratio: (1) Recurrent severe anterior or posterior\nsegment inflammation or uveitis; (2) Patients in whom the IOL may affect the\nability to observe, diagnose, or treat posterior segment diseases; (3)\nSurgical difficulties at the time of cataract extraction, which might increase\nthe potential for complications (e.g., persistent bleeding, significant iris\ndamage, uncontrolled positive pressure, or significant vitreous prolapse or\nloss); (4) A distorted eye due to previous trauma or developmental defect in\nwhich appropriate support of the IOL is not possible; (5) Circumstances that\nwould result in damage to the endothelium during implantation; (6) Suspected\nmicrobial infection; (7) Patients in whom neither the posterior capsule nor\nzonules are intact enough to provide support.\n\nenVista Aspire toric IOL only: Rotation of the IOL away from the intended axis\ncan reduce its astigmatic correction. Misalignment greater than 30° may\nincrease postoperative refractive cylinder. If necessary, IOL positioning\nshould occur prior to capsule fibrosis and IOL encapsulation.\n\nPRECAUTIONS:\n\n\n 1. Neither the safety and effectiveness, nor the effects of the Aspire IOL\noptical design on depth of focus, contrast sensitivity, and subjective visual\ndisturbances (glare, halo, etc.) have been evaluated clinically. MTF testing\nof the Aspire IOL optical design (used in model ETA) may aid the surgeon in\nunderstanding the theoretical image quality expected with the Aspire IOL\ncompared to the enVista monofocal IOL MX60E. However, these do not fully\nassess all aspects of clinical difficulties under all conditions. Surgeons\nmust weigh the potential benefits of the modified optical design of the Aspire\nIOL (model ETA) against the potential for risks associated with a degradation\nin vision quality and the lack of clinical data to characterize the impact of\nthe Aspire IOL optical design on contrast sensitivity and subjective visual\ndisturbance. These considerations may be especially relevant to patients with\ncertain pre-existing ocular conditions (prior corneal refractive surgery,\nirregular corneal astigmatism, severe corneal dystrophy, macular disease,\noptic nerve atrophy, etc.) or intraoperative conditions (posterior capsular\nrupture, complications in which the IOL stability could be compromised,\ninability to place IOL in capsular bag, etc).\n\n 2. The safety and effectiveness of the IOL have not been substantiated in\npatients with pre-existing ocular conditions and intraoperative complications.\nCareful preoperative evaluation and sound clinical judgment should be used by\nthe surgeon to decide the benefit/risk ratio before implanting an IOL in a\npatient with one or more of these conditions. Physicians considering IOL\nimplantation in such patients should explore the use of alternative methods of\naphakic correction and consider IOL implantation only if alternatives are\ndeemed unsatisfactory in meeting the needs of the patient.\n\n 3. Patients with preoperative problems, such as corneal endothelial disease,\nabnormal cornea, macular degeneration, retinal degeneration, glaucoma, and\nchronic drug miosis may not achieve the visual acuity of patients without such\nproblems. The physician must determine the benefits to be derived from IOL\nimplantation when such conditions exist.\n\nAdverse Events: As with any surgical procedure, there is risk involved.\nPotential complications accompanying cataract or implant surgery may include,\nbut are not limited to the following: corneal endothelial damage, infection\n(endophthalmitis), retinal detachment, vitritis, cystoid macular edema,\ncorneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon\ntransient or persistent glaucoma, and secondary surgical intervention.\nSecondary surgical interventions include but are not limited to: lens\nrepositioning, lens replacement, vitreous aspiration or iridectomy for\npupillary block, wound leak repair, and retinal detachment repair.\n\nCAUTION: Federal law restricts these devices to sale by or on the order of a\nphysician.\n\nATTENTION: This is not all you need to know. Please refer to the enVista\nAspire and enVista Aspire toric IOL Directions For Use labeling for a complete\nlisting of indications, full risk and safety information, clinical study\ninformation, etc.\n\nAbout Bausch + Lomb\n\nOur mission is simple – we help people see better to live better, all over\nthe world. For nearly two centuries we’ve evolved with the changing needs of\npatients and customers, and our commitment to innovation and improving the\nstandard of care in eye health has never been stronger. From contact lenses to\nprescription products, over-the-counter options, surgical devices and more,\nwe’re turning bold ideas into better outcomes through passion, perseverance\nand purpose. Learn more at www.bausch.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bausch.com%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=www.bausch.com&index=5&md5=5b488686f2577ef8764769bb61946177)\nand connect with us on Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FBauschandLomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Facebook&index=6&md5=a3c04fe5a494bce2c7a060e823867367)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fbauschlomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=Instagram&index=7&md5=1ab727e903c855d14f97c5a05d13a28e)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbausch-%26-lomb%2F&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=LinkedIn&index=8&md5=c55c05bce7d8833752301c7618a9a9d6)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FBauschLomb&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=X&index=9&md5=5fdaf45c47d9a0d82294b6a6a10730b7)\nand YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fbauschlomb1&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=YouTube&index=10&md5=5c3612cbd8ea0e69b1d4c5d2616f98ea)\n.\n\nReferences\n\n\n 1. Donnenfeld, E., Patel, R., Patterson, M., et al. Real-World Experience with\nEnhanced Monofocal Intraocular Lenses Following Cataract Surgery: A\nMulticenter Retrospective Case Series. Ophthalmol Ther (2026). \nhttps://doi.org/10.1007/s40123-026-01473-3\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40123-026-01473-3&esheet=54597458&newsitemid=20260902448386&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40123-026-01473-3&index=11&md5=b21da6d0aaf6217ffdb17c4e89142b58)\n\n© 2026 Bausch + Lomb.\n\nEASP.0025.USA.26\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260902448386/en/\n(https://www.businesswire.com/news/home/20260902448386/en/)\n\nMedia Contact: \n\nCaryn Marshall\n\ncaryn.marshall@bausch.com \n(mailto:caryn.marshall@bausch.com) \n(908) 493-1381\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-02T11:00:00.255151633Z","server_sent_at_ms":1788346800255},"received_at":"2026-09-02T11:00:00.480Z","source_url":"https://www.businesswire.com/news/home/20260902448386/en/"},"analysis":{"id":"122483","press_release_id":"133591","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Company-announced, low-evidence-tier retrospective case series (84 patients) with no head-to-head comparator or independent verification","No financial metrics disclosed; commercial impact of the publication is unquantified"],"eventType":"operations_update","narrative":"Bausch + Lomb announced the publication of new real-world research on its enVista Aspire and enVista Aspire toric intraocular lenses in the journal Ophthalmology and Therapy, with results showing the enhanced monofocal lenses deliver good distance and functional intermediate vision for cataract patients.\n\nThe multicenter retrospective case series drew on cases from six U.S. cataract surgeons covering 84 patients and 141 eyes. In the enVista Aspire group, 97.2% achieved monocular corrected distance vision of 20/25 or better, and 100% of subjects in both groups reached binocular uncorrected intermediate vision of 20/32 or better, with no serious adverse events recorded.\n\nThe data is marketing-supportive rather than a regulatory or financial event: it adds real-world evidence to an already-launched surgical platform aimed at cataract patients with digital-device demands, and no revenue, guidance, or deal figures were disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Positive real-world data reinforces the enVista Aspire surgical franchise narrative, but this is routine promotional publication rather than a market-moving catalyst."},"keyFigures":{"customDimensions":{"surgeons":6,"study_eyes":141,"study_patients":84,"study_eyes_aspire":88,"toric_low_cylinder_us":"+1.25D","serious_adverse_events":0,"toric_low_cylinder_ous":"+0.90D (IOL plane)","study_eyes_aspire_toric":53,"toric_cdva_20_25_or_better":"94.9%","toric_udva_20_25_or_better":"84.9%","toric_uiva_20_32_or_better":"93%","aspire_cdva_20_25_or_better":"97.2%","aspire_udva_20_25_or_better":"71.3%","aspire_uiva_20_32_or_better":"76.6%","binocular_uiva_20_32_or_better":"100%"}},"quotedText":"Traditional monofocal lenses offer good distance vision, but we know that cataract patients have an increased need and desire for good intermediate vision, particularly given the digital demands of our modern world","namedEntities":{"people":[{"name":"Luc Bonnefoy","role":"President, Surgical, Bausch + Lomb"},{"name":"Eric Donnenfeld, MD","role":"lead study author; ophthalmologist, Ophthalmic Consultants of Connecticut"},{"name":"R. Patel","role":"co-author"},{"name":"M. Patterson","role":"co-author"}],"products":["enVista Aspire","enVista Aspire toric","StableFlex Technology","AccuSet haptic design","enVista monofocal IOL MX60E","Eye Care Professional Hub"],"companies":[{"name":"Bausch + Lomb Corporation","ticker":"BLCO","relationship":"filer; manufacturer of enVista Aspire IOLs"},{"name":"Ophthalmic Consultants of Connecticut","relationship":"lead author affiliation"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a company-issued promotional announcement of supportive real-world evidence for an already-commercialized IOL platform. There is no new approval, no revenue or guidance figure, and no binary outcome; at most it marginally supports surgical-franchise adoption."},"tickerRelevance":{"others":[],"primary":"BLCO"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"promotional-research-publication","sectorWeight":"health-care-devices","issuerAuthored":true,"regulatoryCatalyst":false,"householdBrandBoost":"modest (recognized consumer eye-health brand)"}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"Bausch + Lomb announced the publication of new real-world research on its enVista Aspire and enVista Aspire toric intraocular lenses in the journal Ophthalmology and Therapy, with results showing the enhanced monofocal lenses deliver good distance and functional intermediate vision for cataract patients.\n\nThe multicenter retrospective case series drew on cases from six U.S. cataract surgeons covering 84 patients and 141 eyes. In the enVista Aspire group, 97.2% achieved monocular corrected distance vision of 20/25 or better, and 100% of subjects in both groups reached binocular uncorrected intermediate vision of 20/32 or better, with no serious adverse events recorded.\n\nThe data is marketing-supportive rather than a regulatory or financial event: it adds real-world evidence to an already-launched surgical platform aimed at cataract patients with digital-device demands, and no revenue, guidance, or deal figures were disclosed.","key_figures":{"customDimensions":{"surgeons":6,"study_eyes":141,"study_patients":84,"study_eyes_aspire":88,"toric_low_cylinder_us":"+1.25D","serious_adverse_events":0,"toric_low_cylinder_ous":"+0.90D (IOL plane)","study_eyes_aspire_toric":53,"toric_cdva_20_25_or_better":"94.9%","toric_udva_20_25_or_better":"84.9%","toric_uiva_20_32_or_better":"93%","aspire_cdva_20_25_or_better":"97.2%","aspire_udva_20_25_or_better":"71.3%","aspire_uiva_20_32_or_better":"76.6%","binocular_uiva_20_32_or_better":"100%"}},"named_entities":{"people":[{"name":"Luc Bonnefoy","role":"President, Surgical, Bausch + Lomb"},{"name":"Eric Donnenfeld, MD","role":"lead study author; ophthalmologist, Ophthalmic Consultants of Connecticut"},{"name":"R. Patel","role":"co-author"},{"name":"M. Patterson","role":"co-author"}],"products":["enVista Aspire","enVista Aspire toric","StableFlex Technology","AccuSet haptic design","enVista monofocal IOL MX60E","Eye Care Professional Hub"],"companies":[{"name":"Bausch + Lomb Corporation","ticker":"BLCO","relationship":"filer; manufacturer of enVista Aspire IOLs"},{"name":"Ophthalmic Consultants of Connecticut","relationship":"lead author affiliation"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T11:01:26.877Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"mid-cap","eventGravity":"promotional-research-publication","sectorWeight":"health-care-devices","issuerAuthored":true,"regulatoryCatalyst":false,"householdBrandBoost":"modest (recognized consumer eye-health brand)"}},"durationMs":null,"modelName":"glm-4.7"}}